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ABSTRACT
Background: The proinflammatory cytokines have been implicated in the pathogenesis of heart failure.
Recent studies have shown that β-adrenergic blockade can modulate cytokine production. This study
investigates the different impact of different degrees of sympathetic antagonism on circulating levels of
cytokines in patients with heart failure resulting from ischemic dilated cardiomyopathy (IDC).
Methods and Results: Thirty-five patients with IDC were randomly assigned to receive metoprolol or
carvedilol in an open-label study. Echocardiographic measurements and circulating levels of tumor necrosis
(TNF)-α and interleukin (IL)-1β and IL-6 were obtained at baseline and after 3 months of treatment. The
2 β-blockers significantly improved the left ventricular ejection fraction and reduced end-diastolic and
end-systolic volume. The magnitude of these changes was greater with carvedilol than with metoprolol
(respectively P  .001, P  .05, and P  .05). Both treatments induced a significant decrease in the
levels of cytokines (for all P  .01), but the decrease in TNF-α and IL-1β was more consistent in
the carvedilol group (P  .01).
Conclusion: Our results support the hypothesis that a more complete block of sympathetic activity by
carvedilol induces a greater decrease in the circulating levels of proinflammatory cytokines that could
explain, at least in part, the better improvement in the left ventricular remodelling and systolic function
in patients with IDC.
Key Words: Heart failure, cytokines, sympathetic antagonism, remodeling.The role of neurohormonal overactivation, such as the
norepinephrine and renin-angiotensin-aldosterone system, in
the pathogenesis of heart failure has well been established.
Heart failure is characterized by increased plasma norepi-
nephrine levels and increased sympathetic nervous outflow
to the heart,1 and this sympathoexcitation is a major determi-
nant of prognosis in chronic heart failure.2,3 However, in
addition to the classic neurohormones elaborated in failing
myocardium, investigators have recently focused their atten-
tion on the proinflammatory cytokines. In 1990 Levine et
al.4 demonstrated that circulating levels of tumor necrosis
factor (TNF)-α were elevated in patients with end-stage heart
failure. Elevated circulating levels of other proinflammatory
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doi:10.1016/j.cardfail.2004.07.00621cytokines, such as interleukin (IL)-1β and IL-6, have also
been reported in such patients.5–8 Thus the immune-mediated
mechanism may play an important role in the progression
of heart failure. Moreover, a relationship between TNF-α
and both New York Heart Association (NYHA) functional
class and neurohumoral activation has been detected.9,10 In
a recent study catecholamines stimulation has been shown
to modulate rat myocyte cytokine production.11 During
experimental myocardial infarction–induced heart failure,
β1-selective adrenergic receptor blockade by metoprolol
decreased myocardial expression of TNF-α and IL-1β that
was related to unfavorable ventricular remodelling.12 Like-
wise, in patients with idiopathic dilated cardiomyopathy,
both metoprolol and carvedilol lower the increased levels
of TNF-α and the soluble form of its receptor.13,14 However,
because differential effects of the selective and nonselec-
tive β-adrenergic receptor blockade on sympathetic activ-
ity exist,15,16 a different impact of different β-adrenergic
blocking agents on cytokine production in heart failure may
be speculated .
Thus we investigated the effects of metoprolol (β1-selec-
tive) versus carvedilol (β-nonselective plus α-adrenergic re-
ceptors blockade) on circulating cytokine levels and left3
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from ischemic dilated cardiomyopathy (IDC).
Methods
Study Patients
Thirty-five patients with diagnosis of chronic heart failure sec-
ondary to ischemic heart disease were recruited. All patients were
symptomatic with a minimum of a 6-month history of NYHA class
II, III, or IV and had documented left ventricular (LV) dysfunction
with an LV ejection fraction (LVEF) 40%. Exclusion criteria
included acute coronary syndrome within 3 months or active
angina, valvular disease, hypertension, pulmonary disease, kidney
failure, diabetes, thyroid disease, chronic infections, malignancy or
collagen vascular disease, and history of alcohol. Before the study,
patients were treated for at least 2 weeks with constant doses of
angiotensin-converting enzyme inhibitors, diuretics, and digoxin.
No patients had received anti-inflammatory drugs within the pre-
ceding 2 weeks. All patients gave written informed consent, and
the study was approved by the Ethic Committee of our Institution.
The investigation conforms with the principles outlined in the
Declaration of Helsinki.
Study Protocol
After baseline measurements, patients were randomized in an
open-label fashion to receive either metoprolol tartrate or carvedilol
in addition to the usual treatment. Metoprolol and carvedilol were
started at a dose of 6.25 mg and 3.125 mg, respectively, twice daily.
The dose was uptritated biweekly with a doubling of the twice-
daily dose to a target of 100 mg (50 mg twice daily) of metoprolol
and 50 mg (25 mg twice daily) of carvedilol (if tolerated). These
doses were selected considering previous large multicenter trials
with the 2 drugs17–19,25 and the body weight of our patients (85 kg).
During this period patients were reassessed weekly. Maintenance of
final doses was continued for an additional 3-month period. At
end of this period all measurements were repeated.
Echocardiographic Measurements
Two-dimensional echocardiography was performed with a
phased-array imaging system (ATL HDI system, Bothell, Washing-
ton) equipped with a 2.25-MHz transducer. Each patient was studied
in the left lateral decubitus position after at least 10 minutes of
recumbency. LV end-diastolic (EDV) and end-systolic (ESV) vol-
umes were calculated with the modified Simpson rule and indexed
to the body surface area. All measurements were obtained in
sinus rhythm as a mean of at least 3 consecutive beats. LVEF was
calculated by the formula: LVEF  (EDV ESV)/EDV × 100. All
echocardiographic recordings were made by the same investigator
(F.D.) and were evaluated independently by 2 principal investiga-
tors (M.L. and L.S.).
Enzyme Immunoassays
Blood was collected from an antecubital vein into pyrogen-free
vacuum blood tubes after at least 30 minutes of bed rest. Plasma
was immediately separated by centrifugation at 4C and 1,000 g
for 15 minutes and the serum samples were stored at 80C until
analysis. Plasma levels of TNF-α, IL-1β, and IL-6 were measuredby commercial enzyme amplified sensitivity immunoassay kits ac-
cording to the manufacturer’s specifications (Medgenix Diagnos-
tics, Fleurus, Belgium). Circulating cytokine levels were also
measured in 15 age-matched normal subjects (52 9 years), with
10 male and 5 female selected as the control group. The intra- and
interassay coefficients of variation were less than 10% for all assays.
Statistical Analysis
Values are expressed as mean  standard deviation. Because
the cytokine levels were not normally distributed, these data are
presented as median and 25th to 75th percentiles. Baseline charac-
teristics of the 2 groups of patients were compared by the unpaired
t-test for continuous variables and the Fischer exact test for categori-
cal variables. Analysis of variance was used for between-group
comparison. Within-group comparison was made with the paired
t-test when data were distributed normally and with the Wilcoxon
sign-rank test when tests of normality failed. The NYHA functional
class and the absolute (or the percent) change from baseline in
LVEF, EDV and ESV were compared between 2 treatment groups
with the Mann-Whitney rank-sum test. In the present study a
sample size of 35 patients would have 80% power to detect a
difference of  5.3% in LVEF (α  0.05) using a 2-tailed test. A
P value .05 was considered significant.
Results
The baseline clinical characteristics of the 2 treatment
groups are shown in Table 1. The 2 groups were homoge-
neous in age, gender, or clinical signs of chronic heart
failure. Three patients withdrew during treatment with meto-
prolol, 1 because of poor drug compliance and 2 who were
hospitalized because of increased breathlessness. In the
carvedilol group 2 patients did not complete the study
because of worsening symptoms and they were hospitalized.
None of the remaining 30 patients were admitted to hospital.
In the maintenance phase of treatment the mean daily doses
of metoprolol and carvedilol were, respectively, 93 17
and 45  10 mg. Target doses were achieved in 87% of
patients in the metoprolol group and 80% of patients in the
carvedilol group. The highest dose was 100 and 50 mg and
Table 1. Patients Characteristics
Metoprolol Carvedilol
(n  15) (n  15) P value
Age (y) 57.6  11.9 58.8  11.1 .78
Men/women 9/6 10/5 1.00
NYHA functional class
II 5 4 1.00
III 7 8 1.00
IV 3 3 1.00
Heart rate (beats/min) 90.6  12.3 89.8  10.2 .85
Systolic blood pressure (mm Hg) 119.6 11.8 121.6  13.9 .67
LV ejection fraction (%) 29.7  7.4 29.9  8.2 .94
Pharmacologic agents
ACE inhibitors 15 (100%) 15 (100%) 1.00
Diuretics 15 (100%) 15 (100%) 1.00
Digitalis 10 (67%) 11 (73%) 1.00
Nitrates 13 (87%) 14 (93%) 1.00
ACE, angiotensin-converting enzyme; LV, left ventricular; NYHA, New
York Heart Association.
Sympathetic Antagonism on Cytokine Network • Cinquegrana et al 215the lowest 50 and 25 mg, respectively, for metoprolol
and carvedilol.
Effects on Clinical Variables
The results are shown in Table 2. There was an overall
improvement in NYHA functional class with both metopro-
lol (P  .01) and carvedilol (P  .01) treatment. The differ-
ence between interventions was not statistically significant.
With both β-blockers therapy, heart rate decreased signifi-
cantly from 90.6  12.3 to 68.4 9.8 beats/min (P .001)
after metoprolol and from 89.8  10.2 to 67.8  9.4 beats/
min after carvedilol (P  .001). There was no between-
group difference in the changes. Systolic and diastolic arte-
rial pressure did not change after both treatments.
Effects on LV Remodeling and Systolic Function
After metoprolol LVEF improved from 29.7 7.4% to
31.9  7.6% (P .001), EDV decreased from 121.6 10.5
mL/m2 to 115.3 13 ml/m2 (P  .05) and ESV decreased
from 85.5  13.2 mL/m2 to 78.4  14.3 mL/m2 (P  .01).
After carvedilol LVEF improved from 29.9  8.2 % to
37  10.4% (P  .001), EDV decreased from 127 12.5
mL/m2 to 112.3 12.4 mL/m2 (P  .001) and ESV de-
creased from 89.4  17.2 mL/m2 to 70.7  14.9 mL/m2 (P
 .001). The magnitude of the changes in LVEF, EDV,
and ESV was significantly greater with carvedilol than with
metoprolol, respectively, P  .001 (7  4.2% versus
2.2  2.3%), P  .05 (14.6 11.8 mL/m2 versus
6.3  9.6 mL/m2) and P  .001 (18.7 7.7 mL/m2
versus 7.1  8.4 mL/m2).
Effects on Circulating Cytokines
Serum levels of cytokines were significantly higher in
patients with IDC than in normal subjects. In the control
group TNF-α was 8 (3-12) pg/mL (P  .001), IL-1β 5 (3-
8) pg/mL (P .001), and IL-6 4 (2-6) pg/mL (P .001). The
treatment with either metoprolol or carvedilol was associated
with a significant decrease in TNF-α, IL-1β, and IL-6 (for
all P .01). When data were compared between 2 treatment
groups, a significant difference was found in mean valuesof TNF-α and IL-1β (P .01), although there was a similar
decrease in the levels of IL-6 (Fig. 1).
Thus EDV and ESV decreased concurrently with the cy-
tokine levels after β-blocker therapy. Nevertheless, a major
reduction in EDV and ESV with carvedilol treatment was
in line with a greater decrease of TNF-α and IL-1β but not
IL-6 (Fig. 2).
Discussion
In this study we have demonstrated in patients with
chronic heart failure secondary to coronary artery disease
that both metoprolol and carvedilol significantly improved
symptoms despite a greater increase in LVEF achieved with
carvedilol. In addition, in the carvedilol group we have ob-
served a more substantial benefit on LV remodeling. These
observations are consistent with previous studies either
the placebo-controlled trials or the trials that directly com-
pared the 2 drugs with each other.17–19 In contrast, some
authors observed no difference between metoprolol and
carvedilol treatment in the extent of LVEF changes.20–22
The reason for the different hemodynamic responses could
be related to unlike trial design, etiology distribution (ie,
ischemic cardiomyopathy and dilated idiopathic cardiomy-
opathy) or ethnic derivation. Moreover, in 1 study,22 patients
had already received β-blockers for more than 1 year, so
changes in hemodynamic obtained after cross-over may be
irrelevant. Even though relevant influence on long-term mor-
bidity and mortality is associated with either metoprolol
or carvedilol therapy,23,24 definitive data on comparison ef-
fects of both are now available at the end of the Carvedilol
Or Metoprolol European Trial: carvedilol extends survival
compared with metoprolol.25 An increase in the LVEF was
the most consistent effect of β-blocker therapy in patients with
heart failure. The precise mechanism of this improvement
in LV myocardial performance still remains not entirely
clear, although the effect of treatment on LVEF, even if
small, favorably influences survival.26 Could the differences
observed in our study be related to the minor degree of β1-
receptor blockade with the used dose of metoprolol? The
selected doses of metoprolol and carvedilol were compara-
ble to those that have been employed in many large trialsTable 2. Effects of b Blockade on Clinical Data
Metoprolol (n  15) Carvedilol (n  15)
Baseline 3 Months Baseline 3 Months P value
NYHA functional class
Mean 2.8  0.7 2.2 0.7* 2.9  0.7 1.9  0.6* .15
I/II/III/IV 0/5/7/3 2/7/6/0 0/4/8/3 4/9/2/0
Heart rate (beats/min) 90.6  12.3 68.4 9.8† 89.8  10.2 67.8 9.4† .87
Systolic blood pressure (mm Hg) 119.6  11.8 120.3 11.2 121.6  13.9 118.6  10.4 .67
Diastolic blood pressure (mm Hg) 70.0  8.8 72.3 8.6 72.3  7.7 70.3  6.9 .46
NYHA, New York Heart Association.
P value indicate differences between metoprolol and carvedilol treatment.
*P  .01;
†P  .001 versus baseline.
216 Journal of Cardiac Failure Vol. 11 No. 3 April 2005Fig. 1. Different effects of metoprolol and carvedilol on circulating
levels of cytokines. Data in box plots are given as median and
25th to 75th percentiles. *P  .01 versus baseline.
comparing metoprolol tartrate and carvedilol.17–19,25 In the
Metoprolol CR/XL Randomized Intervention Trial in Con-
gestive Heart Failure study24 the mean dose of metoprolol
succinate (CR/XL) was 159 mg daily that produced a reduc-
tion in heart rate of 14 beats/min. Considering that the
extend-release formulation of metoprolol is 30% to 35%
less bioavailable than immediate release,27 the mean dose of
metoprolol succinate in the Metoprolol CR/XL Randomized
Intervention Trial in Congestive Heart Failure study is equiv-
alent to 111 to 103 mg of metoprolol tartrate. Moreover, the
2 formulations of metoprolol produce similar hemodynamic
effects in patients with heart failure.28 Finally, our data showa decrease in heart rate of 22 beats/min during treatment
with metoprolol tartrate that was comparable to that observed
in the carvedilol group. Thus as extensively debated in
the Carvedilol Or Metoprolol European Trial study,25 we
believe that at the doses of metoprolol tartrate and carvedilol
used in the present study, a comparable degree of β1 receptor
blockade is obtainable and the differences observed between
the 2 drugs were probably not related to under dosing of
metoprolol.
Other results of this study showed that both metoprolol
and carvedilol treatment decreased circulating levels of cy-
tokines including TNF-α, IL-1β, and IL-6 that could in part
explain the clinical benefit of 2 β-blockers. Our observation
could apparently be in contrast with the results of the recent
Anti-TNF Therapy Against Congestive Heart Failure
(ATTACH) trial.29 This study strongly showed the lack of
beneficial effects of TNF-α antagonist infliximab in patients
with heart failure, generating the hypothesis that TNF-α did
not act as a deleterious factor. Infliximab is a recombinant
monoclonal antibody that specifically neutralizes the TNF-
α but not the other circulating cytokine that might maintain
their toxic effects. However, in the ATTACH trial, at 14
weeks, when IL-6 levels were suppressed, LVEF signifi-
cantly increased in patients treated with infliximab versus the
placebo group, but not at 28 weeks when IL-6 levels increased
toward baseline. So, the data of this trial cannot exclude
with certainty that other cytokine, and maybe TNF-α, may
play a role in the pathogenesis of heart failure by the direct
toxic effects on the myocardium as extensively documented
in the literature. In fact, clinical and basic research studies
support the hypothesis that the progression of heart failure
is associated with production of proinflammatory cytok-
ines, including TNF-α, IL-1β, IL-6, and IL-10.4–7,9,10 These
cytokines are capable of modulating cardiovascular struc-
ture and function by several mechanisms that mimic the
phenotypic changes of heart failure including myocyte
apoptosis,30 extracellular matrix alterations,31 and chamber
remodelling.32 So, some analogy exists between the biologic
effects of cytokines and sympathetic overdrive in the failing
heart. A time-dependent elevation of IL-1β and IL-6 after
norepinephrine infusion has also been observed. This was
prevented when combined α- and β-receptor antagonist
carvedilol was infused with norepinephrine.33 The increase
in circulating levels of IL-6 is mainly associated with
the activation of the sympathetic nervous system in patients
with congestive heart failure, even though it is a prognos-
tic predictor independent of plasma norepinephrine and
LVEF.7 Nevertheless, in a recent study achieved on a rabbit
model of myocardial infarction-induced heart failure, Prabhu
et al12 have suggested that prolonged β-adrenergic activation
is a stimulus for myocardial TNF-α and IL-1β expression but
not for IL-6 and that β-blockade with metoprolol decreased
myocardial cytokine expression with a positive effect on
LV remodeling. Similar effects of metoprolol on circu-
lating levels of TNF-α and anti-inflammatory cytokines
were also reported in patients with idiopathic dilated
cardiomyopathy.8,13,14
Sympathetic Antagonism on Cytokine Network • Cinquegrana et al 217Fig. 2. Relationship between left ventricular remodeling and circulating levels of cytokines in the metoprolol (circle) and carvedilol
(triangle) groups at baseline (solid symbols) and at the end of the treatment period (open symbols).But the most interesting finding of our study is the greater
reduction in TNF-α and IL-1β, but not IL-6, after carvedilol
treatment at the same time as the greater reduction in EDV
and ESV. These data suggested that the different degrees of
sympathetic antagonism were associated with the distinct
response on both the circulating levels of cytokines and
remodeling. Carvedilol differs from metoprolol as it is a
nonselective β2 and α1 receptor antagonist. There is evidence
that doxazosin treatment, in addition to metoprolol, produced
identical effects as those seen in patients receiving metopro-
lol alone,34 suggesting that during treatment with carvedilol,
the peripheral α1 antagonism does not appear to be function-
ally important.35 These observations suggested the lack of
influence of α1-blockade properties of carvedilol to deter-
mine differences with metoprolol in heart failure. Recently,
it has been demonstrated that carvedilol induced a significant
reduction in cardiac and systemic norepinephrine spillover,
the indirect measure of norepinephrine release, but not in
patients treated with metoprolol as resulted from a post-
ganglionic effect that is regulated, at least in part, by prejunc-
tional β2-adrenergic receptors.16In view of our data, we speculate that a more complete
sympathetic activity inhibition by carvedilol can produce a
greater block of cytokine production that could most likely
account for different effects on myocardial remodeling and
on clinical outcome. Nevertheless, we cannot exclude that
the different impact of the 2 β-receptors blockade on left
ventricular remodeling might be related to the antioxidant
property of carvedilol.36 Oxidative stress is elevated in fail-
ing myocardium,37,38 and administration of carvedilol causes
a reduction in the oxidative level together with improvement
in cardiac function.38 An important stimulus for increased
oxidative stress is the local production of TNF-α.37 Thus it
is possible to speculate that at least part of the antioxidative
effect of carvedilol could depend on its interaction with
cytokine. But, further studies are needed to identify the
precise relationship between sympathetic overdrive, cytok-
ine, oxidative stress, and remodeling.
Although part of the source of the increase in IL-6 is
the peripheral vascular tissue39 in response to various vaso-
constrictors such as angiotensin II and endothelin-1, the
main origin is leukocytes, including macrophages and
218 Journal of Cardiac Failure Vol. 11 No. 3 April 2005lymphocytes. The similar decrease in levels of IL-6 pro-
duced by either metoprolol or carvedilol in our study popula-
tion, suggests that the failing myocardium-induced increase
in IL-6 could be dependent on prevalent β1-adrenergic recep-
tors stimulation of target cells.
Limitations of the Study
Some limitations of our research must be pointed out. A
major limitation of this study is the relatively small number
of patients. We recognize that a wider sample size could
have improved the power of our results. The severe patient
inclusion criteria have prevented the enrollment of a large
study population in a reasonable period. Nevertheless, the
study sample size did not preclude obtaining statistically sig-
nificant differences between the 2 treatment arms because
of the accuracy of the statistical analysis performed. Al-
though our results are not conclusive, we believe that they
generate an interesting hypothesis needing to be confirmed in
further large trials. Second, this study was not randomized
to treatment but open label. This could be relevant for
subjective parameters as NYHA class, even if we have not
considered symptoms as a primary objective. Furthermore,
echocardiographic determinations and enzyme immunoas-
say analysis were performed in a blinded manner with regard
to the treatment.
Conclusion
The data of the present study suggest that the inhibition
of sympathetic overactivation in patients with dilated cardio-
myopathy secondary to ischemia through both β-blockers
reduces the elevated levels of TNF-α, IL-1β, and IL-6. How-
ever, more marked inhibition of systemic and cardiac sympa-
thetic activity with carvedilol produces a greater decrease
in the circulating levels of proinflammatory cytokines con-
currently with a better effect on the LV remodeling and
systolic function. The differential effects of the nonselective
versus the selective β-adrenergic antagonist on cytokine net-
work will be helpful in explaining, at least in part, the clinical
and hemodynamic outcome of comparative large trials.
However, further studies are needed to verify this interest-
ing hypothesis.
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